Physiomics PLC Contract awards
16 Octubre 2020 - 1:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
16 October 2020
16 October 2020
Physiomics plc
("Physiomics" or "the Company")
Contract awards
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, is pleased to
announce that it has been awarded further contracts of undisclosed
value for projects with existing clients Bicycle Therapeutics plc
("Bicycle") and Merck KGaA ("Merck").
The project with Bicycle is the eighth signed with this
high-profile UK biotech company, spanning four different assets
within its pipeline, and involves population pharmacokinetic
analysis of clinical data from one of these assets. The project
with Merck is an extension of one of the projects previously
announced for calendar year 2020 in what is now the third year of
work under the Master Services Agreement announced in November
2017.
It is anticipated that both projects will be completed over the
next four months.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
For more information please visit:
www.physiomics.co.uk
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKESFEKEFFA
(END) Dow Jones Newswires
October 16, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024